|
||
Article |
Correspondence to James E. Rothman: jr2269{at}columbia.edu
|
|
|---|
| Introduction |
|---|
|
|
|---|
A prevalent feature of HD and other polyQ diseases is the accumulation and aggregation of the mutant protein. These changes lead to the formation of cytoplasmic and nuclear inclusion bodies, the appearance of which indisputably signifies the inability of the cell to properly dispose of the mutant protein. Indeed, overexpression of expanded polyQ proteins has been shown to alter proteasome (Bence et al., 2001) and lysosome function (Qin et al., 2003). Over the past several years, animal models of HD (Yamamoto et al., 2000; Regulier et al., 2003; Harper et al., 2005) and spinocerebellar ataxia type 1 (Xia et al., 2004; Zu et al., 2004) revealed that cells have the capacity to clear these products if the continuous production of the mutant transgene is halted. Invariably, clearance of the protein is accompanied by reversal of the disease-like symptoms in the mice. In light of these findings, it is critical to determine the pathway responsible for alleviating this protein accumulation to define targets to fight these diseases.
To determine the pathway responsible for the clearance of mutant huntingtin (htt), we conducted a two-tiered functional genetic screen. We first used gene arrays to quickly assess the transcriptional changes induced by pathogenic polyQ lengths. Although these changes alone can be somewhat informative, it is difficult to determine the functional relevance of these changes. Thus, we next targeted transcripts of genes that were "increased" with chemically synthesized small interfering RNAs (siRNAs) to determine which of these proteins were required for mutant htt clearance. Those specific proteins revealed by the second screen then became the focus of further investigation.
Of the 56 up-regulated transcripts, 23 were required for mutant htt clearance. Interestingly, the pattern of genes revealed that activation of insulin receptor substrate 2 (IRS-2), a scaffolding protein that mediates the signaling cascades of growth factors such as insulin and insulin-like growth factor 1 (IGF-1; White, 2003), leads to a macroautophagy-mediated clearance of the accumulated polyQ proteins. Clearance is present despite the activation of Akt, mammalian target of rapamycin (mTOR), and p70 S6 kinase. This is surprising because activation of mTOR is an inhibitor of the classic, starvation-induced macroautophagy (Meijer and Codogno, 2004). The significance of this is twofold: first, that macroautophagy in the presence of accumulated proteins can also occur in an mTOR-independent manner; and second, that this represents another important pathway through which factors such as insulin and IGF-1 may exert beneficial effects.
| Results |
|---|
|
|
|---|
|
Next, we determined if the abolition of mutant exon1htt expression would lead to protein clearance. Inhibition of polyQ expression with 100 ng/ml doxycycline (dox) led to clearance of both the soluble and aggregated protein (Fig. 1). Similar to primary cultures derived from the HD94 mice (Martin-Aparicio et al., 2001), within 6 d the inclusions cleared (Fig. 1 and see Fig. 9). Thus, both nonneuronal and neuronal cell lines are capable of clearing the mutant forms of exon1htt. These findings indicate that the elimination of accumulated mutant exon1htt is very slow. Furthermore, because the amount of time required for clearance is similar across cell types, including primary neurons, the process underlying the elimination of this protein may be a general cellular event.
Continuous expression of mutant exon1 htt leads to transcriptional changes
To identify genes that are altered because of expression of mutant exon1htt, we tested our hypothesis that stable expression of 65Q or 103Q leads to transcriptional changes that reflect sequestration and elimination of inclusions. To examine these changes in an unbiased global manner, we determined the genetic profile of the cell lines using Affymetrix gene arrays. Comparisons between exon1htt-65QmCFP (65Q) and 25QmCFP clones (25Q) revealed a total of 70 transcripts increased and 89 transcripts decreased. Comparisons between 103QmCFP (103Q) and 25Q revealed 132 increased and 96 decreased (Fig. 2 a). Common across both pathogenic glutamine lengths was the 56 increased and 42 decreased (Table S1, available at http://www.jcb.org/cgi/content/full/jcb.200510065/DC1). Interestingly, increases were seen in only one proteasomal subunit (PSMD8), but in two lysosome-associated membrane proteins (LAMP1 and 2). The profile also revealed changes in vesicle trafficking, signaling proteins, metabolic proteins, and hypothetical proteins.
|
Eight EST transcripts were excluded from the siRNA screen. For the remaining 48 transcripts, three to four siRNA sequences per gene were individually transfected into two different 65Q and 103Q cell lines. 48 h after transfection, cells were exposed to 100 ng/ml dox for another 48 h to shut down production of new protein and permit 50% of clearance to occur. Cells were fixed and analyzed for the number of inclusions per cell using InCell Analyzer (INCA) 3000 software and calculated for an accumulation index, as described in Materials and methods. An example is shown in Fig. 3.
|
IRS-2 is required for the elimination of mutant exon1htt aggregates
Unexpectedly, knockdown of IRS-2 led to an inhibition of aggregate clearance (Figs. 2 and 3). A scaffolding protein that transmits the phosphatidylinositol 3-kinase (PtdIns3K) signaling of growth factors like IGF-1 and cytokines, IRS-2 knockout mice have also revealed an important role in the brain (Schubert et al., 2003). Western blot analysis confirmed that siRNAs effectively down-regulates the protein (Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb.200510065/DC1). Fig. 3 shows representative images taken from the INCA 3000 of one of the two 103QmCFP clones in the absence of dox, in the presence of dox, and in the presence of dox after transfection with siRNA number 8H06, which is one of the three siRNAs against IRS-2. Quantification using the INCA 3000 software of these images shows that, after transfection of 08H06, the clearance normally observed by abolishing transgene expression is inhibited (Fig. 3 b).
IRS-2 activation leads to enhanced exon1htt clearance
Because elimination of IRS-2 inhibited clearance, IRS-2 activation may stimulate clearance. Therefore, we tested a series of ligands known to activate IRS-2 in the following cells: insulin (Vassen et al., 1999), IGF-1 (Nakamura et al., 2000), and interleukin-4 (IL-4; Loh et al., 1992). All three cells demonstrate a dose-dependent clearance of accumulated polyQ proteins (Fig. 4 a). Unlike our normal clearance paradigm using dox, this clearance occurred despite maintaining continuous expression of exon1htt. As shown in Fig. 4 b, silencing IRS-2 led to a complete inhibition of the enhanced clearance triggered by IGF-1. Western blot analysis also found that IGF-1mediated clearance is inhibited by small interfereing IRS2 (siIRS-2; Fig. S2). Silencing another IRS family member, IRS-1 (White, 2003), had no effect (Fig. 4 c and Fig. S1). Although this result is compelling, we cannot completely eliminate its role because up-regulation of IRS-2 may mask an effect. Similar dependence on IRS-2, but not -1, was observed with the enhanced protein degradation triggered by insulin and IL-4 (unpublished data).
|
We first determined whether the presence of PI3P leads to clearance. Synthetic dipalmitoyl-PI3P has been effectively delivered into the cell using liposomes (Franke et al., 1997; Petiot et al., 2000). Administration of these liposomes to the exon1htt-65Q or 103QmCFP cell lines for 3 d led to a significant decrease in the number of inclusions per cell (Fig. 4 c and not depicted). Coadministration of PI3P with IGF-1 or insulin did not significantly enhance this effect, suggesting that they lie in the same pathway (unpublished data). siRNA against hVps34 effectively eliminated the exon1htt clearance caused by IRS-2 activation (Fig. 4 c). Interestingly, similar to IRS-2, the loss of hVps34 also eliminated the clearance revealed by eliminating transgene expression with dox (unpublished data).
The requirement of hVps34, as well as LAMP1 and 2 (Fig. 2), suggests that macroautophagy is being triggered. Macroautophagy, which we will henceforth refer to as autophagy, is a means by which long-lived cytoplasmic proteins are degraded by the lysosome via engulfment and encasement by a multilamellar structure and fusion to the lysosome (Klionsky and Emr, 2000). Indeed, several studies have previously indicated that the induction of autophagy can lead to the clearance of aggregated polyQ proteins (Ravikumar et al., 2002; Iwata et al., 2005a), especially cytoplasmic ones (Iwata et al., 2005b). It has been previously shown that the inhibition of autophagy elicited by 3-methyladenine (3-MA) is caused by the inhibition of hVps34 (Seglen and Gordon, 1982; Blommaart et al., 1997; Petiot et al., 2000). hVps34 acts in a multiprotein complex that includes p150 and the mammalian orthologue of Apg6, Beclin1 (Liang et al., 1999; Kihara et al., 2001; Tassa et al., 2003). As seen in Fig. 4 b, silencing of Beclin1 abolished the clearance stimulated by IRS-2 activation. To determine if this effect is downstream of class I PtdIns3K activation, we next knocked down the serine/threonine kinase Akt. Akt is a survival kinase that was previously shown to be protective in several diseases, such as amyotrophic lateral sclerosis (ALS) and HD (Humbert et al., 2002; Kaspar et al., 2003; Kanekura et al., 2005; Rangone et al., 2005). Although this siRNA against Akt efficiently knocks down the protein (Fig. S2; Jiang et al., 2003), no effect was seen on the IRS-2mediated clearance (Fig. 4 b). It has previously been shown that Akt phosphorylation of serine 421 on htt leads to fewer aggregates (Humbert et al., 2002; Rangone et al., 2005). Our cell lines express only exon1htt, and thus this residue is not expressed. Perhaps monomeric htt is degraded in an Akt- and proteasome-dependent manner. It is plausible that once an inclusion forms, a different method of protein degradation is required.
IRS-2 activation leads to the activation of autophagy
To further ascertain that IRS-2 activation potentiates autophagy-mediated elimination of the accumulated protein, we examined the effect of established inhibitors of lysosomal degradation and macroautophagy on clearance. As shown in Fig. 5 a, lysosomal inhibitors inhibit the ability of the cell to eliminate the inclusions. 3-MA and wortmannin also eliminated clearance. These findings further demonstrate the importance of lysosomal function in exon1htt clearance and imply a role in autophagy.
|
10% of the inclusion-positive cells had inclusions within LC3-positive vacuoles (Fig. 7 b). Consistent with the enhanced clearance, activation of IRS-2 using IGF-1 significantly increased the frequency of colocalization. siRNA-mediated silencing of IRS-2 and Beclin1 abolished this increase. Silencing Akt or IRS-1, again, had no effect.
|
|
Whole cell lysates were collected from 65QmCFP- or 103QmCFP-expressing cells after exposure to IGF-1 or insulin for 30 min (Fig. 8 b). Phosphospecific antibodies against Akt and p70S6K revealed that, indeed, the targets were rapidly activated in these clones. Therefore, we concluded that the classical autophagic response is intact in our cell lines. Recent work by Scott et al. (2004), however, found that long-term activation of p70S6K can also induce autophagy. To ensure that mTOR signaling is intact in the cell lines, phosphospecific antibodies against mTOR were also used. Phosphorylated mTOR was readily detectable in the presence of mutant exon1htt expression, as well as in the presence or absence of mutant htt expression (Fig. 8 a and not depicted). Amino acid deprivation and rapamycin decreased mTOR phosphorylation in these cells, whereas insulin and IGF-1 inhibited the effect of amino acid withdrawal. Thus, the IGF-1 and insulin lead to the predictive phosphorylation of p70S6K and mTOR.
|
IRS-2 activates autophagy in inducible neuronal mutant exon1htt cell lines
IRS-2 is expressed in all insulin-responsive organs, including the brain. We examined if IRS-2 could activate macroautophagy in response to protein accumulation in neuronal cell lines (Fig. 9). Similar to the HeLa cells, elimination of novel polyQ protein production led to clearance over a period of 6 d. We stimulated IRS-2 using IGF-1 to determine if a similar mechanism was at play. IRS-2 activation using IGF-1 also led to an autophagy-mediated clearance of polyQ proteins in cells of a neuronal lineage. The clearance was accompanied by an increased colocalization of mCFP-positive inclusions in YFP-LC3 autophagosomes. Again, knockdown of Beclin1 inhibited the colocalization of inclusions in the autophagosomes.
|
| Discussion |
|---|
|
|
|---|
|
Activators of IRS-2, such as insulin and IGF-1, have both been shown to strongly promote neuronal survival through stimulation of Akt. Consequently, its efficacy has been tested as such in other neurodegenerative diseases, such as ALS. For example, retroviral delivery of IGF-1 in a mouse model of ALS led to amelioration of the phenotype, together with a diminishing of the accumulated mutant SOD1 (Kaspar et al., 2003). A placebo-controlled trial in American ALS patients found that the progression of functional impairment significantly slowed in the treated patients, with no adverse side effects (Lai et al., 1997). The outcome suggested an IGF-1 dose-dependent treatment effect. For HD, Humbert et al. (2002) have examined the neuroprotective effect of Akt stimulation by transiently transfecting mutant htt into primary neurons. Similar to the findings in ALS, they found that IGF-1 administration led to both a decrease in the number of aggregates formed and a decrease in cell death. The mechanism through which IGF-1 elicited both effects was believed to be directly downstream of Akt (Rangone et al., 2004, 2005). We were able to determine that the autophagocytic clearance can also occur independent of Akt because its knockdown did not eliminate clearance. Monomeric and aggregated proteins may be degraded differently. These findings indicate that the protection conferred by the insulin signaling pathway in diseases with protein accumulation may be twofold; the classical neuroprotective pathway triggered by Akt and the enhanced clearance stimulated by hVps34 activation. Because cytoplasmic inclusions are more readily degraded by autophagy, it is now critical to determine to what extent these inclusions contribute to pathology.
Another point highlighted by this study is that macroautophagy is indeed capable of degrading large inclusions and is stimulated under conditions previously deemed inhibitory. Activation of IRS-2 in the HeLa cell lines was achieved by using insulin, IGF-1, or IL-4. Signaling through these receptors, however, is also known to inhibit mTOR-mediated autophagy through the activation of class I PtdIns3K and mTOR. Nonetheless, there is evidence that autophagy may occur despite mTOR activation. For example, transgenic expression of the autophagosomal marker LC3 demonstrates that in certain tissue autophagosomes constitutively form, even in the absence of starvation (Mizushima et al., 2004). Consistent with these findings, immortalized cells of certain lineages also have a higher basal activity of macroautophagy (Mizushima, 2004). More recently, Iwata et al. (2005a) found that proteasome inhibition was a potent activator of autophagy, although the role of mTOR in the response was not explored. In this study, our findings indicate that macroautophagy is the mechanism by which the aggregates are cleared, despite mTOR activation. This could be achieved if the autophagy regulators downstream of mTOR, such as hVps34, could be activated. Therefore, the activity observed in our results may represent a competition between the inhibitory effects of activating class I versus III kinases. Moreover, Scott et al. (2004) clearly demonstrated in the Drosophila melanogaster fat body that the regulation of autophagy may occur differently from what was previously believed. They found that constitutive activation of p70S6K was indeed required for autophagy, rather than inhibitory as previously described (Klionsky et al., 2005). The presence of expanded polyQ proteins may offset the balance between p70S6K and mTOR, thus, allowing for IRS-2 activation to perpetuate a signal to drive autophagy.
Another possibility is that inclusion formation itself triggers autophagy (Taylor et al., 2003) in an mTOR-dependent fashion, and IRS-2 activation perpetuates this response downstream of mTOR regulation. Indeed, a previous study showed that inclusions can sequester mTOR and, thus, could activate autophagy (Ravikumar et al., 2004). However, in our cell lines, we did not find mTOR sequestration. Nonetheless, differentiation between mTOR dependence and independence is difficult because the activation of IRS-2 is upstream of both the inhibitory and stimulatory signaling. To test this hypothesis, we must first understand how mTOR negatively regulates autophagy in mammalian cells. This is not yet fully defined. In yeast, TOR has been shown to negatively regulate the activation of the Apg13Apg1 complex, a kinase required for autophagy, but it is not certain if this is attributable to direct phosphorylation by TOR (Kamada et al., 2000). Furthermore, in mammalian cells, the orthologues of neither Apg13 nor Apg1 have yet to be identified. mTOR-dependent autophagy has mainly been confirmed in mammalian systems through the use of chemical inhibitors such as rapamycin. Chemical compounds that directly activate mTOR are not available.
In conclusion, by starting with a nonhypothesis-driven approach, we were able to discover that the regulation underlying degradation of accumulated proteins differs from the regulation underlying conditions of starvation. Furthermore, this work demonstrates that we can no longer assume that regulatory mechanisms studied under nonpathogenic conditions are static; cells compensate when confronted with toxic conditions. Accordingly, we have found that the insulin-signaling pathway may be an important avenue through which this might be achieved. Indeed, activation of IRS-2 has been an attractive target for the treatment of type II diabetes, and thus this line of research may also benefit other disorders. In any case, it is clear from these studies that more information regarding the importance of lysosomal degradation pathways such as autophagy in neuronal systems is absolutely crucial. Controlling these pathways that degrade mutant htt will allow us to finally begin to treat this terrible disease.
| Materials and methods |
|---|
|
|
|---|
Creation of cell line
N2a were selected to be tTA-positive by transfection with PCMV-tTA-IRES-neo and selection with 800 µg/ml G418. PolyQ cell lines were created by cotransfecting Hela and N2a with tetO-htt (25Q, 65Q, or 103Q) exon1-mCFP and PTk-hygro (CLONTECH Laboratories, Inc.) and then selected with hygromycin using 800 and 200 µg/ml, respectively. 100 ng/ml dox was also maintained in the culture media during selection to maintain suppression of transgene expression. HeLa cells were maintained in DME with 10% FCS, whereas N2a cells were maintained in 50% DME/50% Optimem in 10% FCS.
RNA preparation and gene arrays
Cells were plated in a 100-mm dish, harvested using 100 µL TRIzol reagent (Invitrogen) and isolated per the manufacturer's instructions. RNA was resuspended and further purified using the RNAeasy kit (QIAGEN). RNA was labeled and hybridized onto human U133A chips at the Genome Core Facility at Memorial Sloan Kettering Cancer Center (MSKCC). Array results were analyzed using GeneSpring 2.0 (Agilent Technologies) and an Affymetrix software package 5.0.
Transfection
siRNAs were designed using an algorithm designed by Jagla et al. (2005). siRNA were created at either Integrated DNA Technologies or the Functional Proteonomics Project at MSKCC. Scramble siRNA sequences were purchased from Dharmacon. A final concentration of 10 or 20 nM of siRNAs was used for silencing. Cells were transfected using OligofectAMINE per the manufacturer's instructions. 7.5 x 103 cells were plated in 96-well ViewPlates (Packard Instrument Co.) and transfected the next day. 48 h after transfection, cells were split across two wells and treated with dox. Cells were examined 48 h later. Transfection of plasmid DNA was accomplished using LipofectAMINE per the manufacturer's instructions. Compounds were administered 48 h after transfection unless otherwise noted.
Image analysis with the INCA 3000
For the high throughput screen, images were collected on the INCA 3000 (GE Healthcare). Cells in 96-well ViewPlates were fixed for 10 min with 4% PFA, and the nuclei were stained using 1 µM Hoechst 333342 for 30 min. After scanning the plates, images were analyzed using the granularity analysis module on the accompanying software. In brief, the granularity analysis quantifies the number of inclusions (grains) within a cell, using a two-color strategy to identify individual cells and to analyze associated grains. After recognizing the objects, in this case the Hoechst-positive nuclei, the algorithm next identifies, using a specified size range (in pixels) and fluorescent intensity gradient, the grain in the proximity of the object. Both the Ngrains (number of qualifying grains per cell) and the fraction of fluorescent within the qualifying grains gave similar results. To calculate the accumulation index used in Fig. 2, values were first normalized as a percentage of control for scramble siRNAtransfected cells treated with 2 d of 100 ng/ml dox, and set to 0 by subtracting 100%. This would permit comparison across all of the experiments conducted and a quick assessment of the direction of the changean increase in accumulation (>0) or an increase in clearance (<0). A gene was considered required for clearance when the absolute value of accumulation index was greater than two standard deviations of the Scramble siRNA + 2 d dox. Each siRNA was transfected on 8 wells per 96-well plate, and each experiment was repeated five to eight times. Cell viability was determined through several measures. First, we examined the number of cells per well scanned. If a drug or siRNA led to significantly fewer cells, they were initially considered toxic. If this toxicity consistently appeared across experiments, we next confirmed toxicity using an inclusion/exclusion assay of cell death, known as a LIVE/DEAD assay (Invitrogen).
Other image analysis
Cells were grown on glass (HeLa) or poly-D-lysinecoated (N2a) coverslips in 24-well plates. Cells were fixed for 10 min with 4% PFA. Nuclei were stained with Hoechst 33342 for 30 min, and membranes were stained using Alexa Fluor 633labeled cholera toxin subunit B obtained from Invitrogen. Images were acquired using a confocal microscope (TCS SP2; Leica) at 63x magnification, along with the accompanying software package. Data acquisition was performed using National Institutes of Health Image 4.0. Analysis of variance (ANOVA) and post hoc analyses were conducted using Statview 5.0 (SAS Institute, Inc.).
PI3P liposomes
Synthetic dipalymitoyl-PI3Ps (Matreya) were dried together with phosphatidylserine at a 1:1 concentration under argon and vacuum and resuspended in 25 mM Hepes, 100 mM KCl, and 1 mM EDTA to a total lipid concentration of 800 µM. Liposomes were freeze-thawed, then manually extruded through two 50-nm polycarbonate membranes. PI3P/phosphatidylserine liposomes were administered to cells at 20 µM for 3 d, fixed, and assessed for clearance.
Measuring degradation of long-lived proteins in response to amino acid deprivation
This protocol was adapted from previously reported protocols (Talloczy et al., 2002; Scarlatti et al., 2004). Cells were incubated for 18 h at 37°C with 0.5 µCi/ml L-[14C]valinesupplemented media. Cells were rinsed with HBSS to remove unincorporated radioisotopes and then chased in fresh media overnight to allow degradation of short-lived proteins. Cells were rinsed in HBSS + 10 mM Hepes and incubated for 4 h with either full media ± rapamycin, 20 mM PI3P liposomes, or HBSS + 10 mM Hepes ± 3-MA,20 µM PI3P liposomes, 100 nM insulin, or 100 nM IGF-1. Cells were scraped and, using TCA, protein was precipitated from both the incubation media and the cells. Proteolysis was assessed as the acid-soluble radioactivity divided by the radioactivity maintained in the precipitate.
Online supplemental material
Fig. S1 shows cell lines that were monitored for cell death using the LIVE/DEAD assay. Fig. S2 shows whole cell lysates from transfected cells that were run on SDS-PAGE gels, transferred to PVDF membranes, and probed with the antibodies as noted. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200510065/DC1.
| Acknowledgments |
|---|
We thank the Mathers Foundation (J.E. Rothman), the Helen Hay Whitney Foundation (A. Yamamoto), and the High Q. Foundation and the Hereditary Disease Foundation for their generous support.
Submitted: 12 October 2005
Accepted: 26 January 2006
| References |
|---|
|
|
|---|
Andrejewski, N., E.L. Punnonen, G. Guhde, Y. Tanaka, R. Lullmann-Rauch, D. Hartmann, K. von Figura, and P. Saftig. 1999. Normal lysosomal morphology and function in LAMP-1-deficient mice. J. Biol. Chem. 274:1269212701.
Arrasate, M., S. Mitra, E.S. Schweitzer, M.R. Segal, and S. Finkbeiner. 2004. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 431:805810.[CrossRef][Medline]
Backer, J.M. 2000. Phosphoinositide 3-kinases and the regulation of vesicular trafficking. Mol. Cell Biol. Res. Commun. 3:193204.[CrossRef][Medline]
Bence, N.F., R.M. Sampat, and R.R. Kopito. 2001. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:15521555.
Blommaart, E.F., U. Krause, J.P. Schellens, H. Vreeling-Sindelarova, and A.J. Meijer. 1997. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur. J. Biochem. 243:240246.[Medline]
Chaussade, C., L. Pirola, S. Bonnafous, F. Blondeau, S. Brenz-Verca, H. Tronchere, F. Portis, S. Rusconi, B. Payrastre, J. Laporte, and E. Van Obberghen. 2003. Expression of myotubularin by an adenoviral vector demonstrates its function as a phosphatidylinositol 3-phosphate [PtdIns(3)P] phosphatase in muscle cell lines: involvement of PtdIns(3)P in insulin-stimulated glucose transport. Mol. Endocrinol. 17:24482460.
Elbashir, S.M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494498.[CrossRef][Medline]
Franke, T.F., D.R. Kaplan, L.C. Cantley, and A. Toker. 1997. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 275:665668.
Gossen, M., A.L. Bonin, S. Freundlieb, and H. Bujard. 1994. Inducible gene expression systems for higher eukaryotic cells. Curr. Opin. Biotechnol. 5:516520.[CrossRef][Medline]
Harper, S.Q., P.D. Staber, X. He, S.L. Eliason, I.H. Martins, Q. Mao, L. Yang, R.M. Kotin, H.L. Paulson, and B.L. Davidson. 2005. From the cover: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA. 102:58205825.
Humbert, S., E.A. Bryson, F.P. Cordelieres, N.C. Connors, S.R. Datta, S. Finkbeiner, M.E. Greenberg, and F. Saudou. 2002. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves huntingtin phosphorylation by Akt. Dev. Cell. 2:831837.[CrossRef][Medline]
Iwata, A., J.C. Christianson, M. Bucci, L.M. Ellerby, N. Nukina, L.S. Forno, and R.R. Kopito. 2005a. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proc. Natl. Acad. Sci. USA. 102:1313513140.
Iwata, A., B.E. Riley, J.A. Johnston, and R.R. Kopito. 2005b. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. Chem. 280:4028240292.
Jacinto, E., and M.N. Hall. 2003. Tor signalling in bugs, brain and brawn. Nat. Rev. Mol. Cell Biol. 4:117126.[CrossRef][Medline]
Jagla, B., N. Aulner, P.D. Kelly, D. Song, A. Volchuk, A. Zatorski, D. Shum, T. Mayer, D.A. De Angelis, O. Ouerfelli, et al. 2005. Sequence characteristics of functional siRNAs. RNA. 11:864872.
Jana, N.R., M. Tanaka, G. Wang, and N. Nukina. 2000. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet. 9:20092018.
Jana, N.R., E.A. Zemskov, G. Wang, and N. Nukina. 2001. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10:10491059.
Jiang, Z.Y., Q.L. Zhou, K.A. Coleman, M. Chouinard, Q. Boese, and M.P. Czech. 2003. Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing. Proc. Natl. Acad. Sci. USA. 100:75697574.
Kabeya, Y., N. Mizushima, T. Ueno, A. Yamamoto, T. Kirisako, T. Noda, E. Kominami, Y. Ohsumi, and T. Yoshimori. 2000. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19:57205728.[CrossRef][Medline]
Kamada, Y., T. Funakoshi, T. Shintani, K. Nagano, M. Ohsumi, and Y. Ohsumi. 2000. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. J. Cell Biol. 150:15071513.
Kanekura, K., Y. Hashimoto, Y. Kita, J. Sasabe, S. Aiso, I. Nishimoto, and M. Matsuoka. 2005. A Rac1/phosphatidylinositol 3-kinase/Akt3 anti-apoptotic pathway, triggered by AlsinLF, the product of the ALS2 gene, antagonizes Cu/Zn-superoxide dismutase (SOD1) mutant-induced motoneuronal cell death. J. Biol. Chem. 280:45324543.
Kaspar, B.K., J. Llado, N. Sherkat, J.D. Rothstein, and F.H. Gage. 2003. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 301:839842.
Kihara, A., Y. Kabeya, Y. Ohsumi, and T. Yoshimori. 2001. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep. 2:330335.[CrossRef][Medline]
Kim, M., H.S. Lee, G. LaForet, C. McIntyre, E.J. Martin, P. Chang, T.W. Kim, M. Williams, P.H. Reddy, D. Tagle et al. 1999. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 19:964973.
Klionsky, D.J., and S.D. Emr. 2000. Autophagy as a regulated pathway of cellular degradation. Science. 290:17171721.
Klionsky, D.J., A.J. Meijer, P. Codogno, T.P. Neufeld, and R.C. Scott. 2005. Autophagy and p70S6 Kinase. Autophagy. 1:5961.[Medline]
Lai, E.C., K.J. Felice, B.W. Festoff, M.J. Gawel, D.F. Gelinas, R. Kratz, M.F. Murphy, H.M. Natter, F.H. Norris, and S.A. Rudnicki. 1997. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology. 49:16211630.
Liang, X.H., S. Jackson, M. Seaman, K. Brown, B. Kempkes, H. Hibshoosh, and B. Levine. 1999. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 402:672676.[CrossRef][Medline]
Loh, J.E., C.H. Chang, W.L. Fodor, and R.A. Flavell. 1992. Dissection of the interferon gamma-MHC class II signal transduction pathway reveals that type I and type II interferon systems share common signalling component(s). EMBO J. 11:13511363.[Medline]
Maffucci, T., A. Brancaccio, E. Piccolo, R.C. Stein, and M. Falasca. 2003. Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. EMBO J. 22:41784189.[CrossRef][Medline]
Martin-Aparicio, E., A. Yamamoto, F. Hernandez, R. Hen, J. Avila, and J.J. Lucas. 2001. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J. Neurosci. 21:87728781.
Meijer, A.J., and P. Codogno. 2004. Regulation and role of autophagy in mammalian cells. Int. J. Biochem. Cell Biol. 36:24452462.[CrossRef][Medline]
Mizushima, N. 2004. Methods for monitoring autophagy. Int. J. Biochem. Cell Biol. 36:24912502.[CrossRef][Medline]
Mizushima, N., A. Yamamoto, M. Matsui, T. Yoshimori, and Y. Ohsumi. 2004. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol. Biol. Cell. 15:11011111.
Nakagawa, I., A. Amano, N. Mizushima, A. Yamamoto, H. Yamaguchi, T. Kamimoto, A. Nara, J. Funao, M. Nakata, K. Tsuda, et al. 2004. Autophagy defends cells against invading group A Streptococcus. Science. 306:10371040.
Nakamura, K., A. Hongo, J. Kodama, Y. Miyagi, M. Yoshinouchi, and T. Kudo. 2000. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res. 60:760765.
Pelkmans, L., E. Fava, H. Grabner, M. Hannus, B. Habermann, E. Krausz, and M. Zerial. 2005. Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. Nature. 436:7886.[CrossRef][Medline]
Petiot, A., E. Ogier-Denis, E.F. Blommaart, A.J. Meijer, and P. Codogno. 2000. Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J. Biol. Chem. 275:992998.
Qin, Z.H., Y. Wang, K.B. Kegel, A. Kazantsev, B.L. Apostol, L.M. Thompson, J. Yoder, N. Aronin, and M. DiFiglia. 2003. Autophagy regulates the processing of amino terminal huntingtin fragments. Hum. Mol. Genet. 12:32313244.
Rangone, H., G. Poizat, J. Troncoso, C.A. Ross, M.E. MacDonald, F. Saudou, and S. Humbert. 2004. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur. J. Neurosci. 19:273279.[CrossRef][Medline]
Rangone, H., R. Pardo, E. Colin, J.A. Girault, F. Saudou, and S. Humbert. 2005. Phosphorylation of arfaptin 2 at Ser260 by Akt Inhibits PolyQ-huntingtin-induced toxicity by rescuing proteasome impairment. J. Biol. Chem. 280:2202122028.
Ravikumar, B., R. Duden, and D.C. Rubinsztein. 2002. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11:11071117.
Ravikumar, B., C. Vacher, Z. Berger, J.E. Davies, S. Luo, L.G. Oroz, F. Scaravilli, D.F. Easton, R. Duden, C.J. O'Kane, and D.C. Rubinsztein. 2004. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36:585595.[CrossRef][Medline]
Regulier, E., Y. Trottier, V. Perrin, P. Aebischer, and N. Deglon. 2003. Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. Hum. Mol. Genet. 12:28272836.
Saltiel, A.R. 2001. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell. 104:517529.[CrossRef][Medline]
Saudou, F., S. Finkbeiner, D. Devys, and M.E. Greenberg. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 95:5566.[CrossRef][Medline]
Scarlatti, F., C. Bauvy, A. Ventruti, G. Sala, F. Cluzeaud, A. Vandewalle, R. Ghidoni, and P. Codogno. 2004. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J. Biol. Chem. 279:1838418391.
Schu, P.V., K. Takegawa, M.J. Fry, J.H. Stack, M.D. Waterfield, and S.D. Emr. 1993. Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science. 260:8891.
Schubert, M., D.P. Brazil, D.J. Burks, J.A. Kushner, J. Ye, C.L. Flint, J. Farhang-Fallah, P. Dikkes, X.M. Warot, C. Rio, et al. 2003. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci. 23:70847092.
Scott, R.C., O. Schuldiner, and T.P. Neufeld. 2004. Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev. Cell. 7:167178.[CrossRef][Medline]
Seglen, P.O., and P.B. Gordon. 1982. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl. Acad. Sci. USA. 79:18891892.
Sun, X.J., M. Miralpeix, M.G. Myers Jr., E.M. Glasheen, J.M. Backer, C.R. Kahn, and M.F. White. 1992. Expression and function of IRS-1 in insulin signal transmission. J. Biol. Chem. 267:2266222672.
Sun, X.J., L.M. Wang, Y. Zhang, L. Yenush, M.G. Myers Jr., E. Glasheen, W.S. Lane, J.H. Pierce, and M.F. White. 1995. Role of IRS-2 in insulin and cytokine signalling. Nature. 377:173177.[CrossRef][Medline]
Talloczy, Z., W. Jiang, H.W. Virgin, D.A. Leib, D. Scheuner, R.J. Kaufman, E.L. Eskelinen, and B. Levine. 2002. Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proc. Natl. Acad. Sci. USA. 99:190195.
Tanaka, Y., G. Guhde, A. Suter, E.L. Eskelinen, D. Hartmann, R. Lullmann-Rauch, P.M. Janssen, J. Blanz, K. von Figura, and P. Saftig. 2000. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature. 406:902906.[CrossRef][Medline]
Tassa, A., M.P. Roux, D. Attaix, and D.M. Bechet. 2003. Class III phosphoinositide 3-kinaseBeclin1 complex mediates the amino acid-dependent regulation of autophagy in C2C12 myotubes. Biochem. J. 376:577586.[CrossRef][Medline]
Taylor, J.P., F. Tanaka, J. Robitschek, C.M. Sandoval, A. Taye, S. Markovic-Plese, and K.H. Fischbeck. 2003. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum. Mol. Genet. 12:749757.
Vassen, L., W. Wegrzyn, and L. Klein-Hitpass. 1999. Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene. Mol. Endocrinol. 13:485494.
Virbasius, J.V., X. Song, D.P. Pomerleau, Y. Zhan, G.W. Zhou, and M.P. Czech. 2001. Activation of the Akt-related cytokine-independent survival kinase requires interaction of its phox domain with endosomal phosphatidylinositol 3-phosphate. Proc. Natl. Acad. Sci. USA. 98:1290812913.
Waelter, S., A. Boeddrich, R. Lurz, E. Scherzinger, G. Lueder, H. Lehrach, and E.E. Wanker. 2001. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell. 12:13931407.
Wang, G.H., K. Mitsui, S. Kotliarova, A. Yamashita, Y. Nagao, S. Tokuhiro, T. Iwatsubo, I. Kanazawa, and N. Nukina. 1999. Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuroreport. 10:24352438.[Medline]
White, M.F. 2003. Insulin signaling in health and disease. Science. 302:17101711.
Xia, H., Q. Mao, S.L. Eliason, S.Q. Harper, I.H. Martins, H.T. Orr, H.L. Paulson, L. Yang, R.M. Kotin, and B.L. Davidson. 2004. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10:816820.[CrossRef][Medline]
Yamamoto, A., J.J. Lucas, and R. Hen. 2000. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 101:5766.[CrossRef][Medline]
Zacharias, D.A., J.D. Violin, A.C. Newton, and R.Y. Tsien. 2002. Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells. Science. 296:913916.
Zu, T., L.A. Duvick, M.D. Kaytor, M.S. Berlinger, H.Y. Zoghbi, H.B. Clark, and H.T. Orr. 2004. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24:88538861.